Food-Derived Longevity Supplement Primeadine® GF Launches at Erewhon
Spermidine is a naturally occurring molecule that activates autophagy — a mechanism that mimics the effects of fasting by clearing out damaged cells and encouraging the regeneration of healthier ones. It also targets other key drivers of aging, including chronic inflammation, mitochondrial and stem cell dysfunction, and gut microbiome imbalances.
As we age, the body's natural production of spermidine declines, making us more reliant on plant sources in our diet.
Sourced from the longevity islands of Okinawa, Japan, Primeadine GF is a first-of-its-kind, gluten-free spermidine supplement sourced from a unique strain of Okinawan chlorella. It also contains two other autophagy-activating ingredients, nobiletin (from 'Shikuwasa' citrus lime peel) and curcumin (from turmeric).
'We're thrilled to bring Primeadine GF to Erewhon, where customers are deeply intentional about what they put in their bodies,' said Leslie Kenny, CEO and founder of Oxford Healthspan. 'This partnership is especially meaningful because both Oxford Healthspan and Erewhon are rooted in Japanese wellness traditions, from the macrobiotic movement that inspired Erewhon's founding to the Japan-sourced ingredients that power our supplements. We share a commitment to aging well through food-based approaches that honor both science and nature.'
Primeadine GF delivers a range of science-backed benefits: Supports cellular renewal
Promotes cognitive clarity, hormonal balance, and immune resilience
Enhances skin, hair, and nail vitality from the inside out
Backed by Oxford scientists and recommended by leading clinicians and nutritionists
Tested for pesticides, heavy metals and toxins, and free from fillers and flow agents
Primeadine GF is now available at all Erewhon locations across Southern California.
Learn more about Primeadine GF at oxfordhealthspan.com .
About Oxford Healthspan
Oxford Healthspan is a women-led, science-backed longevity supplement company dedicated to helping people age on their own terms by delivering premium, food-derived longevity supplements that harmonize Eastern wisdom with modern longevity science. With a mission to revolutionize healthy aging, Oxford Healthspan sources only the highest-quality ingredients from Japan to ensure purity, potency, and safety. Learn more at oxfordhealthspan.com and follow @oxfordhealthspan on Instagram.
About Erewhon
Erewhon is an independent, family-owned Certified B Corp and Certified Organic Retailer with 10 locations across Southern California. Since 1968, Erewhon has been providing organic, ethically-sourced foods to the communities it serves. It's committed to sourcing healthy, nutrient-dense products, backing local growers and brands, and supporting the environment. Recognized for its uncompromising quality standards and customer service, Erewhon sustains a community centered in caring, curiosity, and positive change. For more information, visit erewhon.com.
MEDIA CONTACT:Lisa Lazarczyk, LAZ PR
Tel: 617.838.7327 or [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass., August 21, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Collaboration is at the core of the Quanterix Accelerator Laboratory," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners." The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About QuanterixQuanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at View source version on Contacts Media Contact Marissa Klaassenmedia@ Sign in to access your portfolio
Business Wire
3 hours ago
- Business Wire
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' Share 'Collaboration is at the core of the Quanterix Accelerator Laboratory,' said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. 'Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa ® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa ® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa ® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at
Yahoo
3 hours ago
- Yahoo
U.S. already has the critical minerals it needs – but they're being thrown away, new analysis shows
Colorado School of Mines researchers call for more research, development and policy to increase critical mineral recovery in new Science article GOLDEN, Colo., Aug. 21, 2025 (GLOBE NEWSWIRE) -- All the critical minerals the U.S. needs annually for energy, defense and technology applications are already being mined at existing U.S. facilities, according to a new analysis published today in the journal Science. The catch? These minerals, such as cobalt, lithium, gallium and rare earth elements like neodymium and yttrium, are currently being discarded as tailings of other mineral streams like gold and zinc, said Elizabeth Holley, associate professor of mining engineering at Colorado School of Mines and lead author of the new paper. "The challenge lies in recovery," Holley said. "It's like getting salt out of bread dough – we need to do a lot more research, development and policy to make the recovery of these critical minerals economically feasible." To conduct the analysis, Holley and her team built a database of annual production from federally permitted metal mines in the U.S. They used a statistical resampling technique to pair these data with the geochemical concentrations of critical minerals in ores, recently compiled by the U.S. Geological Survey, Geoscience Australia and the Geologic Survey of Canada. Using this approach, Holley's team was able to estimate the quantities of critical minerals being mined and processed every year at U.S. metal mines but not being recovered. Instead, these valuable minerals are ending up as discarded tailings that must be stored and monitored to prevent environmental contamination. 'This is a brand-new view of 'low hanging fruit' – we show where each critical mineral exists and the sites at which even 1 percent recovery of a particular critical mineral could make a huge difference, in many cases dramatically reducing or even eliminating the need to import that mineral,' Holley said. The analysis in Science looks at a total of 70 elements used in applications ranging from consumer electronics like cell phones to medical devices to satellites to renewable energy to fighter jets and shows that unrecovered byproducts from other U.S. mines could meet the demand for all but two – platinum and palladium. Among the elements included in the analysis are: Cobalt (Co): The lustrous bluish-gray metal, a key component in electric car batteries, is a byproduct of nickel and copper mining. Recovering less than 10 percent of the cobalt currently being mined and processed but not recovered would be more than enough to fuel the entire U.S. battery market. Germanium (Ge): The brittle silvery-white semi-metal used for electronics and infrared optics, including sensors on missiles and defense satellites, is present in zinc and molybdenum mines. If the U.S. recovered less than 1 percent of the germanium currently mined and processed but not recovered from U.S. mines, it would not have to import any germanium to meet industry needs. The benefits of enhanced recovery are not only economic and geopolitical but also environmental, Holley said – recovering these critical minerals instead of sending them to tailings piles would reduce the environmental impact of mine waste and open more opportunities for reuse in construction and other industries. 'Now that we know which sites are low-hanging fruit, we need to conduct detailed analyses of the minerals in which these chemical elements reside and then test the technologies suitable for recovery of those elements from those specific minerals,' Holley said. 'We also need policies that incentivize mine operators to incorporate additional processing infrastructure. Although these elements are needed, their market value may not be sufficient to motivate operators to invest in new equipment and processes without the right policies in place.' Co-authors on the paper are Karlie Hadden, PhD candidate in geology; Dorit Hammerling, associate professor of applied mathematics and statistics; Rod Eggert, research professor of economics and business; Erik Spiller, research professor of mining engineering; and Priscilla Nelson, professor of mining engineering. To read the full paper, "Byproduct recovery from US metal mines could reduce import reliance for critical minerals," go to For access to illustrations/graphs related to this study, contact About Mines Colorado School of Mines is a public R1 research university focused on applied science and engineering, producing the talent, knowledge and innovations to serve industry and benefit society – all to create a more prosperous future. A photo accompanying this announcement is available at CONTACT: Contact: Erich Kirshner, Media Relations Specialist / 303.921.6733Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
